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Neutrophils migrate into the bowel lumen as a result of an 
inflammatory process, and the level of fecal calprotectin 
strongly correlates with the degree of intestinal inflamma-
tion.2 Moreover, calprotectin concentration distinguishes 
IBD from normal findings or functional disorders such as 
IBS.3 Several studies have shown that the calprotectin level 
can be used to identify IBD,4-7 to assess the response to IBD 
therapy,7-14 and to predict an IBD relapse.7,15-18 Furthermore, 
fecal calprotectin analysis is noninvasive and easily acces-
sible in comparison to colonoscopy with a biopsy, which is 
the gold standard for assessment of gastrointestinal inflam-
mation.19,20 
Since identification of fecal calprotectin as a potential 
biomarker, many types of calprotectin test kits have been 
developed. ELISAs have been typically used to quantify fecal 
calprotectin. Recently, quantitative immunochromatograph-
ic point-of-care tests or immunoassays were developed as 
INTRODUCTION
Fecal calprotectin has been proposed as a candidate diag-
nostic marker for discrimination between IBD and IBS. Cal-
protectin is a heterodimer of the calcium-binding proteins 
S100A8 and S100A9 and is present mainly in neutrophils.1 
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Background/Aims: Several studies have found that the measurement of fecal calprotectin is useful for the early diagnosis of 
inflammatory bowel disease (IBD). We compared the effectiveness of three different fecal calprotectin kits for initial diagnosis 
in patients with suspected IBD. Methods: We enrolled 31 patients with IBD (18 Crohn’s disease [CD], 11 ulcerative colitis [UC], 
and two intestinal Behçet’s disease), five with irritable bowel syndrome (IBS), and five with other colitis (four infectious colitis 
and one intestinal tuberculosis). Diagnosis was based on clinical, laboratory, and endoscopic examinations. Fecal samples 
were obtained at the first diagnosis and calprotectin levels were measured using three different kits (Quantum Blue® Calpro-
tectin, EliATM Calprotectin, and RIDASCREEN® Calprotectin). Results: The overall accuracy for differentiating IBD from IBS or 
other colitis was 94% and 91%, respectively, for Quantum Blue® (cutoff, 50 mg/g); 92% and 89%, respectively, for EliATM (cutoff, 
50 mg/g); and 82% and 76%, respectively, for RIDASCREEN® (cutoff, 50 mg/g). In patients with CD, the results of Quantum Blue® 
Calprotectin and EliATM Calprotectin correlated significantly with levels of the Crohn’s disease activity index (Spearman’s rank 
correlation coefficient, r=0.66 and r=0.49, respectively). In patients with UC, the results of EliATM Calprotectin correlated signifi-
cantly with the Mayo score (r=0.70). Conclusions: Fecal calprotectin measurement is useful for the identification of IBD. The 
overall accuracies of the three fecal calprotectin kits are comparable. (Intest Res 2016;14:305-313)
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a reliable alternative to the more time-consuming ELISA 
methods.21,22 Nonetheless, these calprotectin test kits vary in 
characteristics, and few data are available regarding clinical 
comparison. A comparison of different calprotectin test kits 
may help clinicians in choosing the appropriate assay. 
We designed this study to evaluate the initial diagnostic 
ability of three fecal calprotectin kits−Quantum Blue® Cal-
protectin, EliATM Calprotectin, and RIDASCREEN® Calpro-
tectin−in different bowel diseases. Furthermore, we tested 
whether the results produced by these fecal calprotectin kits 
correlate with disease activity and location of CD or UC.
METHODS
1. Subjects
We screened 52 patients who visited Severance Hospital 
from July to December 2014 for a workup because of ab-
dominal pain, changes in bowel habits, and/or anorectal 
bleeding. We excluded patients who met any of the following 
criteria: incomplete colonoscopy, inability to collect fecal 
samples, colorectal cancer, history of bowel resection, an 
uncertain diagnosis after colonoscopy, or regular intake of 
aspirin and/or NSAIDs. Of a total of 52 screened patients, 
11 were excluded: two for a lack of fecal samples, one for 
colorectal cancer, and eight for unclear diagnoses (Fig. 1). 
Finally, 41 patients were enrolled in this study.
The patients were classified into three groups: IBD (CD, 
UC, and intestinal Behçet’s disease), IBS, and “other coli-
tis.” The latter group was defined as patients with a bowel 
disease other than IBD and IBS and included patients with 
infectious colitis and intestinal tuberculosis. The diagnosis of 
a bowel disease was established on the basis of a clinical his-
tory, laboratory results, endoscopic findings, pathology, and 
radiologic analyses according to the diagnostic criteria. We 
also assessed disease severity using CDAI in patients with 
CD and the Mayo score in patients with UC. CRP was quan-
tified by an immunoturbidimetric method and the cutoff 
was 8 mg/L. All the enrolled patients underwent complete 
colonoscopy. The data were collected in a prospective man-
ner and analyzed retrospectively.
The study protocol adheres to the 1975 Declaration of 
Helsinki guidelines and was approved by the Institutional 
Review Board of Yonsei University College of Medicine 
(approval number: 4-2015-1117). Each participant or legal 
guardian provided written informed consent for diagnosis 
and treatment.
2. Fecal Calprotectin
Fecal samples were obtained at the first diagnosis and fe-
cal calprotectin levels were measured with three kits: Quan-
tum Blue® Calprotectin, EliATM Calprotectin, and RIDAS-
CREEN® Calprotectin. The laboratory technician conducting 
the tests was blinded to the patient’s clinical information. All 
the tests were performed according to the manufacturers’ 
instructions.
The Quantum Blue® Calprotectin kit (Bühlmann Labo-
ratories, Basel, Switzerland) was provided by WOONGBEE 
MeDiTech (Seongnam, Korea). Fecal samples were diluted 
1:50, and the cutoff was 50 mg/g. EliATM Calprotectin (Phadia 
AB, Uppsala, Sweden) was provided by Phadia Korea (Seoul, 
Korea). Fecal samples were diluted 1:100, and the cutoff was 
50 mg/g. The RIDASCREEN® Calprotectin kit (R-Biopharm 
AG, Darmstadt, Germany) was provided by Asan Pharma-
ceuticals (Seoul, Korea). Fecal samples were diluted 1:50, 
and the cutoff was 50 mg/g.
 3. Statistical Analysis
The comparison among the three different calprotectin 
test kits was conducted using Passing and Bablok regression 
52 Total patients
11 Patients excluded
2 Lack of fecal samples
1 Colorectal cancer
8 Unclear diagnosis
31 IBD
18 CD
11 UC
2 Intestinal Behcet s disease
5 IBS 5 Other colitis
4 Infectious colitis
1 Intestinal tuberculosis
Fig. 1. Selection of the study subjects.
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and Spearman’s rank correlation. Clinical and laboratory 
data on the patients were presented as mean±SD, range, or 
n (%), when appropriate. The Mann-Whitney test was used 
to compare the results of quantitative assays for fecal calpro-
tectin and CRP between each disease group and to evaluate 
a possible correlation between fecal calprotectin concen-
tration and disease location in patients with IBD (a P-value 
<0.017 was considered statistically significant according to 
Bonferroni’s correction). The test performance of the three 
different calprotectin kits and a CRP assay was evaluated 
by means of sensitivity, specificity, positive and negative 
predictive values, and overall accuracy. The association be-
tween disease activity and fecal calprotectin was evaluated 
by means of Spearman’s rank correlation coefficient (r) for 
nonparametric correlations. A P -value <0.05 was assumed 
to denote statistical significance. All statistical analyses were 
performed in the SPSS software, version 12.0 (SPSS Inc., Chi-
cago, IL, USA), except for the Passing and Bablok regression, 
which was analyzed in the MedCalc software, version 16.2.1 
(MedCalc, Ostend, Belgium). Vertical scatter plots were con-
structed using GraphPad Prism, version 6 (Graphpad Soft-
ware Inc., LaJolla, CA, USA).
RESULTS
1. Patients’ Characteristics
A total of 41 patients were analyzed in this study. Clinical 
characteristics of these patients are shown in Table 1. Twelve 
of the patients with CD had ileocolonic involvement, one had 
colonic involvement, and five had ileal involvement. Of the 
patients with UC, five had proctitis, and six had pancolitis.
Mean disease activity of CD patients was 199.3 points 
(range, 133−393 points). There were 14 patients (78%) with 
CDAI >150. Mean disease activity among UC patients was 
6.4 (range, 3−10). Five patients (45%) had Mayo scores of 
3 to 5 (mildly active disease), and six patients (55%) had 
scores of 6 to 10 (moderately active disease).
The “other colitis” group consisted of four patients with 
infectious colitis and one patient with intestinal tuberculosis. 
Endoscopic findings revealed that the patients with infec-
tious colitis had mucosal redness, erosions, and/or ulcers, 
and the patient with intestinal tuberculosis had circular ul-
cers with scars.
2. Comparison of the Methods
The correlation analysis was performed among Quantum 
Blue® (as a standard value), EliATM, and RIDASCREEN® 
(Fig. 2). Between Quantum Blue® and EliATM, the intercept 
of the regression line according to the Passing and Bablok 
regression was 7.19 (95% CI, 23.82−39.23) and no significant 
deviation from 0 was present. The slope was 0.39 (95% CI, 
0.32−0.47) and a significant deviation from 1 was present. 
The intercept and slope were 54.70 (95% CI, 1.20−107.67) 
and 0.09 (95% CI, 0.07−0.17) between Quantum Blue® and 
RIDASCREEN®, and a significant deviation from 0 and 1 
was present. Spearman’s rank correlation coefficient was 
0.90 (P<0.0001; 95% CI, 0.82−0.95) between Quantum Blue® 
and EliATM and 0.72 (P<0.0001; 95% CI, 0.52−0.85) between 
Quantum Blue® and RIDASCREEN®. Although the three 
assays correlated significantly, the slopes and intercepts dif-
fered in pairwise comparisons.
3. Test Characteristics of Fecal Calprotectin and CRP
The results of quantitative assays for fecal calprotectin are 
presented in Fig. 3. The mean calprotectin level according 
to Quantum Blue® was 3,384±3,450 mg/g (range, 218−9,960 
mg/g) in IBD, 120±190 mg/g (range, 30−459 mg/g) in IBS, and 
Table 1. Baseline Characteristics of the Study Subjects
Variable
IBD
IBS Other colitisa
CD UC Intestinal BD
No. of patients 18 11 2 5 5
Female sex 4 (22) 4 (36) 2 (100) 2 (40) 1 (20)
Age (yr) 22±5 (15–31) 41±21 (19–74) 54±21 (39–69) 17±12 (5–31) 38±24 (11–69)
Disease activityb 199.3±67.7 (133–393)  6.4±2.3 (3–10) - - -
Values are presented as number (%) or mean±SD (range). 
aSee the METHODS section regarding the definition.
bCDAI for CD and Mayo score for ulcerative colitis. 
BD, Behçet’s disease.
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227±184 mg/g (range, 30−394 mg/g) in “other colitis.” Accord-
ing to EliATM, the mean calprotectin level was 1,476±1,127 
mg/g (range, 47−3,000 mg/g) in IBD, 54±74 mg/g (range, 
15−187 mg/g) in IBS, and 88±58 mg/g (range, 15−156 mg/g) 
in “other colitis.” According to RIDASCREEN®, the mean 
calprotectin level was 467±360 mg/g (range, 0−800 mg/g) in 
IBD, 11±13 mg/g (range, 0−27 mg/g) in IBS, and 73±48 mg/g 
(range, 0−114 mg/g) in “other colitis.” The mean CRP concen-
tration was 17.0±21.8 mg/L (range, 0.3−72.7 mg/L) in IBD, 
0.9±0.8 mg/L (range, 0.4−2.3 mg/L) in IBS, and 0.9±0.8 mg/
L (range, 0.4−2.3 mg/L) in “other colitis.” Fecal calprotectin 
levels according to the three kits and CRP levels were sig-
nificantly higher in patients with IBD than in patients with 
IBS (P <0.017, Bonferroni’s correction). Fecal calprotectin 
concentrations determined by the three different kits and 
CRP levels were not different between IBS and “other colitis” 
(P>0.017 according to Bonferroni’s correction).
4. Test Performance of the Three Calprotectin Kits and 
     CRP Assay
The test performance (sensitivity/specificity/positive pre-
dictive values/negative predictive values) and overall accu-
racy in distinguishing between IBD and IBS or “other colitis” 
is summarized in Table 2. For differentiation of IBD from IBS, 
the overall accuracy was 97%/94%/84%/58% for Quantum 
Blue®, EliATM, RIDASCREEN®, and CRP, respectively. For 
discrimination of IBD and “other colitis,” the overall accuracy 
was 91%/89%/76%/58% for Quantum Blue®, EliATM, RIDAS-
CREEN®, and CRP, respectively. Neither fecal calprotectin 
levels nor the CRP levels were helpful for differentiation of 
IBS and “other colitis” (accuracy, 22%−50%).
5. Correlation of Fecal Calprotectin Levels with Disease 
     Activity among Patients with IBD
Data on the correlation between fecal calprotectin levels 
determined by the three kits and disease activity are de-
picted in Fig. 4. In patients with CD, Quantum Blue® Calpro-
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tectin and EliATM Calprotectin correlated significantly with 
CDAI (P=0.004 and P=0.041, respectively; r=0.66 and r=0.49, 
respectively). The RIDASCREEN® calprotectin level did not 
correlate statistically significantly with CDAI. In patients 
with UC, the mean time interval between fecal sampling 
and colonoscopy was 12.7 days (median, 10 days; range, 
0−32 days). EliATM Calprotectin correlated significantly with 
the Mayo score (P =0.017, r=0.70), whereas Quantum Blue® 
Calprotectin and RIDASCREEN® calprotectin results did not 
correlate with the Mayo score.
6. Correlation of Fecal Calprotectin Levels with the 
      Disease Location in Patients with IBD
We also explored the relation between fecal calprotectin 
levels and the disease location in patients with IBD (Fig. 
5). CD was located in the ileum in five patients, in the co-
lon in one patient, and in the ileocolon in 12 patients. The 
mean calprotectin level according to Quantum Blue® was 
1,156±975 mg/g (range, 256−2,250 mg/g) in the ileum, 4,450 
mg/g in the colon, and 5,769±3,192 mg/g (range, 1,555−9,960 
mg/g) in the ileocolon. According to EliATM, the mean cal-
protectin concentration was 569±576 mg/g (range, 53−1,471 
mg/g) in the ileum, 2,103 mg/g in the colon, and 2,202±834 
mg/g (range, 833−3,000 mg/g) in the ileocolon. According to 
RIDASCREEN®, the mean calprotectin concentration was 
214±335 mg/g (range, 0−800 mg/g) in the ileum, 709 mg/g 
in the colon, and 796±13 mg/g (range, 758−800 mg/g) in the 
ileocolon. According to all three fecal calprotectin kits, fecal 
calprotectin levels were significantly higher in CD patients 
with ileocolonic involvement than in CD patients with ileal 
involvement (all P =0.004). CDAI did not differ statistically 
significantly when stratified by disease location (all P>0.05). 
UC was identified as a type of proctitis in five patients, and 
pancolitis in six patients. The mean calprotectin level ac-
cording to Quantum Blue® was 2,166±3,817 mg/g (range, 
218−8,990 mg/g) in proctitis and 2,353±3,742 mg/g (range, 
376−9,000 mg/g) in pancolitis. According to EliATM, the mean 
calprotectin concentration was 947±1,199 mg/g (range, 
116−3,000 mg/g) in proctitis and 1,515±1,273 mg/g (range, 
283−3,000 mg/g) in pancolitis. According to RIDASCREEN®, 
the mean calprotectin concentration was 235±328 mg/g 
(range, 0−800 mg/g) in proctitis and 226±295 mg/g (range, 
0−800 mg/g) in pancolitis. For all three kits, fecal calprotectin 
levels of patients with UC did not differ by disease location. 
The Mayo score was higher in pancolitis UC than in proc-
titis UC (7.7±2.1 vs. 4.8±1.5, respectively, P =0.033). In two 
patients with intestinal Behçet’s disease, one patient’s lesion 
was located in the ileocecal valve, and the other patient’s le-
sions were located in the ileocecal valve, terminal ileum, and 
colon. Calprotectin levels of the former and latter were 736 
mg/g and 1,128 mg/g according to Quantum Blue®, 47 mg/g 
and 500 mg/g according to EliATM, and untestable (due to a 
lack of fecal samples) and above 800 mg/g according to RI-
DASCREEN®, respectively. 
DISCUSSION
Calprotectin, which was first described in 1980, has been 
proposed as a possible diagnostic marker of IBD.23 Conven-
tional testing for calprotectin involves a laboratory ELISA, 
but the ELISA method is time-consuming, has a long turn-
around time, and requires expertise. Recently, quantitative 
immunochromatographic point-of-care tests or quantitative 
enzyme immunoassays have become available as alterna-
tives to the time-consuming ELISA. These tests can be per-
formed in the clinic within 15 minutes. Only a small amount 
of stool is required, and the testing can be performed on 
stool samples kept for up to 1 week at room temperature 
because fecal calprotectin is resistant to bacterial degrada-
tion. Therefore, patients can bring a sample from home and 
receive a result on fecal calprotectin in a single visit.
In 2012, Coorevits et al.21 reported a comparison of a new-
ly developed quantitative immunochromatographic point-
of-care test (Quantum Blue®) with an established ELISA test 
in terms of distinguishing organic from functional bowel 
Table 2. Test Performance and Overall Accuracy of the Three Fecal Calprotectin Kits and CRP Assay
IBD vs. IBS IBD vs. other colitis IBS vs. other colitis
Calprotectin (µg/g), Quantum Blue® 100/80/97/100/97 100/40/91/100/91 20/40/25/33/30
Calprotectin (µg/g), EliATM 97/80/97/80/94 97/40/91/67/89 20/40/25/33/30
Calprotectin (µg/g), RIDASCREEN® 82/100/100/44/84 82/40/88/29/76 0/40/0/33/22
CRP (mg/L) 52/100/100/25/58 52/100/100/25/58 0/100/0/50/50
Sensitivity/specificity/positive predictive values/negative predictive values/overall accuracy (%). See the METHODS section regarding the definition of 
“other colitis.” 
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Fig. 4. (A-C) Correlation of the disease activity index with fecal calprotectin levels in IBD. In patients with CD, Quantum Blue® Calprotectin and EliATM 
Calprotectin correlated significantly with the levels of CDAI. In patients with UC, EliATM Calprotectin correlated significantly with the Mayo score. r, 
Spearman’s rank correlation coefficient.
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diseases. The determination coefficient (R2) for 128 samples 
was 0.89 in the comparison of the methods, and the concor-
dance ratio was 89.4%. The point-of-care test was shown to 
be a reliable alternative to the ELISAs. 
Recently, a new quantitative enzyme immunoassay, the 
EliATM calprotectin assay, was developed, and Oyaert et al.22 
compared this assay with the point-of-care test among 183 
patients with suspected IBD. Test performance of the EliATM 
calprotectin assay was statistically equivalent to that of the 
point-of-care test. 
Another quantitative enzyme immunoassay, the RI-
DASCREEN® calprotectin assay, has not been validated in 
patients with suspected IBD. The present study compared 
these three fecal calprotectin kits to evaluate their initial di-
agnostic ability in patients with IBD, IBS, or “other colitis.”
All three fecal calprotectin kits were superior to CRP in 
distinguishing IBD from IBS or “other colitis.” Overall accu-
racy for differentiating IBD from IBS or “other colitis” was the 
best for Quantum Blue® Calprotectin (97%/91%), followed 
by EliATM Calprotectin (94%/89%) and RIDASCREEN® Cal-
protectin (84%/76%). 
Some articles about a comparison of calprotectin test kits 
were published recently. Mirsepasi-Lauridsen et al.24 com-
pared three ELISA calprotectin tests among IBD patients 
and reported that the specificity of CALPRO, EK-CAL, and 
HK325 is 96%, 74%, and 28%, respectively. Therefore, the 
three calprotectin assays tested in the present study are 
comparable to an ELISA for diagnostic purposes. Labaere et 
al.25 compared three rapid immunochromatographic assays 
(including Quantum Blue®), two ELISAs, and one automat-
ed immunoassay (EliATM) in terms of diagnosis and follow-
up of IBD. Sensitivity and specificity for the diagnosis of IBD 
were 83% and 68% for Quantum Blue® and 75% and 95% for 
EliATM, respectively. The present study revealed similar clini-
cal performance.
On the other hand, efficacy of fecal-calprotectin kits does 
not seem to be satisfactory in discriminating IBD from the 
“other colitis” group, considering the low specificity observed 
(all 40%). This is probably because the present study has 
a small sample size, and the study population is heteroge-
neous in terms of diagnosis and severity of the diseases. If 
the sample size of the “other colitis” group were larger, then 
the accuracy of fecal calprotectin kits might decrease as 
reported in another study.26 The three fecal calprotectin kits 
were not statistically helpful in discriminating between IBS 
and “other colitis” although calprotectin levels of patients 
with “other colitis” were found to be numerically higher than 
those of patients with IBS, as reported in other studies.22,26
Among patients with CD, results of Quantum Blue® Cal-
protectin and EliATM Calprotectin correlated significantly 
with CDAI. The RIDASCREEN® calprotectin data, however, 
did not correlate with CDAI, possibly because the upper 
limit of RIDASCREEN® Calprotectin is lower than that of 
the other two tests. Among patients with UC, only EliATM 
Calprotectin correlated significantly with the Mayo score. 
EliATM Calprotectin appeared to better reflect disease activity 
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ment (all P-values, 0.004). (B) UC. For all three kits, fecal calprotectin levels did not differ by disease location.
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in patients with UC than in patients with CD. Costa et al.27 
reported that fecal calprotectin shows a higher correlation 
with disease activity of UC than with that of CD. 
We also evaluated the correlation between fecal calpro-
tectin levels and disease location in patients with IBD. There 
was a significant difference in calprotectin levels between 
CD patients with ileocolonic involvement and those with 
ileal involvement. This result is consistent with a report by 
Schoepfer et al.,28 who studied the correlation of fecal calpro-
tectin with the simple endoscopic score for CD among 140 
patients with CD. Nevertheless, a comparison of colonic in-
volvement with other affected locations must be confirmed 
in studies with a larger sample size because only one patient 
in the present study had colonic involvement. 
The cost of these three calprotectin kits is $20−33 per 
sample tested (Quantum Blue®>EliATM>RIDASCREEN®). 
Nonetheless, the final cost can vary depending on the num-
ber of samples tested at a time because each kit is packaged 
differently (25 tests/kit for Quantum Blue®, 48 tests/kit for 
EliATM, and 96 tests/kit for RIDASCREEN®).
Finally, when we evaluated the correlation between differ-
ent calprotectin kits, the correlation coefficients were high, 
but when we performed regression analysis, significant dif-
ferences were observed. This finding is in line with the data 
reported in other studies.25,29 Therefore, as authors of those 
studies pointed out, direct comparison of absolute calprotec-
tin levels between different kits is inappropriate, and the use 
of the same kit is desirable during the follow-up of patients 
with IBD.
This study has several limitations. First, this study has a 
relatively small sample size. Therefore, larger studies will be 
necessary to confirm our results. Second, colonic involve-
ment was present in only one patient with CD, and this situ-
ation limited the comparison between colonic involvement 
and other affected locations. Nevertheless, the trends and 
results of analysis regarding correlation of fecal calprotectin 
with the disease location are consistent with data from other 
studies.21
In conclusion, fecal calprotectin tests are useful for distin-
guishing IBD from IBS or “other colitis” (in the descending 
order of performance): Quantum Blue® Calprotectin, EliATM 
Calprotectin, and RIDASCREEN® Calprotectin.
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